FLOWER-MI | COMPLETE | Compare-Acute | DANAMI-3-PRIMULTI | ||
Angio | FFR | ||||
Dates | 2016–2018 | 2011–2015 | 2011–2015 | 2011–2014 | |
No of patients | 1171 | 4041 | 885 | 627 | |
Median follow-up (mths) | 12 | 36 | 12 | 27 | |
Design | Angio (>50%) vs FFR | Angio (≥70%)* vs OMT | FFR vs OMT | FFR vs OMT | |
FFR ≥0.80 | 44% | – | 46% | 31% | |
Composite primary outcome (no/%) | Death, non-fatal MI, unplanned admission and urgent revasc | CV death, MI, ischaemia-driven revasc | Death, non-fatal MI, any revasc, CVA/TIA | Death, non-fatal MI, ischaemia-driven revasc | |
24 (4.2) | 32 (5.5) | 179 (8.9) | 23 (7.8) | 40 (13) | |
Event rate with revascularisation (%)† | |||||
Death | 1.7 | 1.5 | 1.6 | 1.4 | 4.7 |
CV death | NR | 1.0 | 1.0 | 1.6 | |
MI | 1.7 | 3.1 | 1.9 | 2.4 | 4.7 |
*Only a minority of patients with moderate stenoses (50%–69%) that would have mandated FFR measurement were enrolled in COMPLETE.
†Event rates for COMPLETE shown as % per person-year as reported by the authors, for comparison with the 12-month follow-up of FLOWER-MI.
COMPLETE, Complete versus Culprit-Only Revascularisation Strategies to Treat Multivessel Disease after Early PCI for STEMI; CV, cardiovascular; CVA, cerebrovascular accident; DANAMI-3-PRIMULTI, Third Danish Study of Optimal Acute Treatment of Patients with STEMI: Primary PCI in Multivessel Disease; FFR, fractional flow reserve; FLOWER-MI, FLOW Evaluation to Guide Revascularization in Multi-vessel ST-elevation Myocardial Infarction; MI, myocardial infarction; NR, not formally reported; OMT, optimal medical therapy; PCI, percutaenous coronary intervention; STEMI, ST-elevation myocardial infarction; TIA, transient ischaemic attack.